Semaglutide biosimilar(Tonghua Dongbao)

司美格鲁肽生物类似药（通化东宝）

Report date: 2022/03/30 14:20:37

Base Information

Drug NameSemaglutide biosimilar(Tonghua Dongbao)
Drug Alias Namesemaglutida biosimilar索马鲁肽生物类似药semaglutidum biosimilar索玛鲁肽生物类似药司美鲁肽生物类似药 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A